Selected article for: "current work and vaccine development"

Author: Tulchinsky, Theodore H.
Title: Maurice Hilleman: Creator of Vaccines That Changed the World
  • Cord-id: o9zxl2o3
  • Document date: 2018_3_30
  • ID: o9zxl2o3
    Snippet: Maurice Ralph Hilleman (1919–2005) was one of the greatest microbiologists/vaccinologists of all time. He played a key role in developing vaccines for Asian flu in 1957 and Hong Kong flu in 1968. Over six decades, most of which were spent at Merck & Company, his leadership and innovations blazed new trails in virology, epidemiology, immunology, cancer research, and vaccine development that were unmatched. His work resulted in current vaccines used for the prevention of measles, mumps, hepatiti
    Document: Maurice Ralph Hilleman (1919–2005) was one of the greatest microbiologists/vaccinologists of all time. He played a key role in developing vaccines for Asian flu in 1957 and Hong Kong flu in 1968. Over six decades, most of which were spent at Merck & Company, his leadership and innovations blazed new trails in virology, epidemiology, immunology, cancer research, and vaccine development that were unmatched. His work resulted in current vaccines used for the prevention of measles, mumps, hepatitis A and B, chickenpox, meningitis, and pneumonia, which have saved millions of lives across the globe. The need for close cooperation between public and private agencies, including donors, to promote research in vaccinology is reemphasized by recent global health crises such as the Ebola and Zika viruses, as well as the annual influenza virus threats. Eradication of many diseases is feasible, but requires political support for resources, vaccine development and harmonization of vaccination policies, to be achievable. Hilleman worked with many collaborators in academic centers, in industrial management, with which he led his research and development team to produce world-changing achievements.

    Search related documents:
    Co phrase search for related documents
    • adolescent child and low income: 1, 2, 3, 4, 5, 6, 7
    • adolescent child and low income country: 1
    • adolescent child and low medium: 1, 2
    • adolescent child and low medium high: 1
    • adolescent child and low medium high income: 1
    • adolescent child and low priority: 1, 2
    • liver disease and long chain: 1
    • liver disease and long period: 1, 2
    • liver disease and long term survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • liver disease and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver disease and low medium: 1, 2, 3
    • liver disease and low medium high: 1, 2
    • liver disease and lupus erythematosus: 1, 2, 3, 4, 5, 6
    • liver disease risk and long chain: 1
    • liver disease risk and long term survival: 1
    • liver disease risk and low income: 1, 2
    • liver disease risk and lupus erythematosus: 1
    • lmic high priority and low income: 1